Zhejiang Hisun Pharmaceutical Co.,Ltd. (600267.SH) has released its financial report for the third quarter of 2026, revealing that the company achieved operating revenue of 6.521 billion yuan in the first three quarters, representing a year-on-year decline of 17.70%. The net profit attributable to shareholders of the listed company reached 1.146 billion yuan, a year-on-year increase of 148.56%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses stood at 982 million yuan, up 100.11% year-on-year. Basic earnings per share came in at 0.99 yuan.
During the first three quarters, the changes in the company's performance were primarily driven by the combined effects of improved profitability in its core business and a one-time disposal gain. Sales of innovative drugs and pet medications grew steadily, and the increase in sales volume unleashed production scale effects, leading to a continuous decline in production costs, optimized product structure, and sustained improvements in overall operational efficiency. Meanwhile, the disposal gain from the transfer of 100% equity in Provincial Pharmaceutical further boosted the net profit attributable to shareholders of the listed company.
Comments